Last reviewed · How we verify
Anti-CD123 CAR NK cells
CAR-T cell therapy targeting CD123
CAR-T cell therapy targeting CD123 Used for Acute myeloid leukemia.
At a glance
| Generic name | Anti-CD123 CAR NK cells |
|---|---|
| Sponsor | Chongqing Precision Biotech Co., Ltd |
| Drug class | CAR-T cell therapy |
| Target | CD123 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Chimeric antigen receptor T cells engineered to recognize and kill cancer cells expressing CD123.
Approved indications
- Acute myeloid leukemia
Common side effects
- Cytokine release syndrome
- Neutropenia
- Anemia
Key clinical trials
- Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN (PHASE1)
- Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-CD123 CAR NK cells CI brief — competitive landscape report
- Anti-CD123 CAR NK cells updates RSS · CI watch RSS
- Chongqing Precision Biotech Co., Ltd portfolio CI